Literature DB >> 22147261

Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.

Ling Ren1, Sung-Hyeok Hong, Qing-Rong Chen, Joseph Briggs, Jessica Cassavaugh, Satish Srinivasan, Michael M Lizardo, Arnulfo Mendoza, Ashley Y Xia, Narayan Avadhani, Javed Khan, Chand Khanna.   

Abstract

Ezrin links the plasma membrane to the actin cytoskeleton where it plays a pivotal role in the metastatic progression of several human cancers; however, the precise mechanistic basis for its role remains unknown. Here, we define transitions between active (phosphorylated open) and inactive (dephosphorylated closed) forms of Ezrin that occur during metastatic progression in osteosarcoma. In our evaluation of these conformations we expressed C-terminal mutant forms of Ezrin that are open (phosphomimetic T567D) or closed (phosphodeficient T567A) and compared their biologic characteristics to full-length wild-type Ezrin in osteosarcoma cells. Unexpectedly, cells expressing open, active Ezrin could form neither primary orthotopic tumors nor lung metastases. In contrast, cells expressing closed, inactive Ezrin were also deficient in metastasis but were unaffected in their capacity for primary tumor growth. By imaging single metastatic cells in the lung, we found that cells expressing either open or closed Ezrin displayed increased levels of apoptosis early after their arrival in the lung. Gene expression analysis suggested dysregulation of genes that are functionally linked to carbohydrate and amino acid metabolism. In particular, cells expressing closed, inactive Ezrin exhibited reduced lactate production and basal or ATP-dependent oxygen consumption. Collectively, our results suggest that dynamic regulation of Ezrin phosphorylation at amino acid T567 that controls structural transitions of this protein plays a pivotal role in tumor progression and metastasis, possibly in part by altering cellular metabolism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147261      PMCID: PMC3867810          DOI: 10.1158/0008-5472.CAN-11-0210

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Apoptosis: an early event in metastatic inefficiency.

Authors:  C W Wong; A Lee; L Shientag; J Yu; Y Dong; G Kao; A B Al-Mehdi; E J Bernhard; R J Muschel
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

2.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma.

Authors:  C Khanna; J Khan; P Nguyen; J Prehn; J Caylor; C Yeung; J Trepel; P Meltzer; L Helman
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

3.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.

Authors:  C Khanna; J Prehn; C Yeung; J Caylor; M Tsokos; L Helman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 4.  Osteosarcoma: a review of diagnosis, management, and treatment strategies.

Authors:  David S Geller; Richard Gorlick
Journal:  Clin Adv Hematol Oncol       Date:  2010-10

5.  Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain.

Authors:  K Hamada; T Shimizu; T Matsui; S Tsukita; T Hakoshima
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

6.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency.

Authors:  M D Cameron; E E Schmidt; N Kerkvliet; K V Nadkarni; V L Morris; A C Groom; A F Chambers; I C MacDonald
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

7.  Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.

Authors:  T Mäkitie; O Carpén; A Vaheri; T Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

8.  Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.

Authors:  Chand Khanna; Jerry J Jaboin; Elias Drakos; Maria Tsokos; Carol J Thiele
Journal:  In Vivo       Date:  2002 Mar-Apr       Impact factor: 2.155

Review 9.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 10.  Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency.

Authors:  A F Chambers; G N Naumov; S A Vantyghem; A B Tuck
Journal:  Breast Cancer Res       Date:  2000-07-21       Impact factor: 6.466

View more
  27 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

2.  Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.

Authors:  Yisila Mu; Haoshaqiang Zhang; Lixin Che; Kun Li
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

Review 3.  Sphingolipid regulation of ezrin, radixin, and moesin proteins family: implications for cell dynamics.

Authors:  Mohamad Adada; Daniel Canals; Yusuf A Hannun; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2013-07-12

4.  Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.

Authors:  Motonari Nomura; Nino Rainusso; Yi-Chien Lee; Brian Dawson; Cristian Coarfa; Ruolan Han; Jeffrey L Larson; Ryan Shuck; Lyazat Kurenbekova; Jason T Yustein
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

5.  Ezrin Inhibition Up-regulates Stress Response Gene Expression.

Authors:  Haydar Çelik; Gülay Bulut; Jenny Han; Garrett T Graham; Tsion Z Minas; Erin J Conn; Sung-Hyeok Hong; Gary T Pauly; Mutlu Hayran; Xin Li; Metin Özdemirli; Ayşe Ayhan; Michelle A Rudek; Jeffrey A Toretsky; Aykut Üren
Journal:  J Biol Chem       Date:  2016-05-02       Impact factor: 5.157

6.  Protein phosphatase 2A Cα regulates proliferation, migration, and metastasis of osteosarcoma cells.

Authors:  Di Yang; Hirohiko Okamura; Hiroyuki Morimoto; Jumpei Teramachi; Tatsuji Haneji
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

7.  Decreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells.

Authors:  Qunyan Jin; Guangming Liu; Phillip P Domeier; Wei Ding; Kathleen M Mulder
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

8.  Discovery of biomarkers for osteosarcoma by proteomics approaches.

Authors:  Yoshiyuki Suehara; Daisuke Kubota; Kazutaka Kikuta; Kazuo Kaneko; Akira Kawai; Tadashi Kondo
Journal:  Sarcoma       Date:  2012-11-21

9.  Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells.

Authors:  Xiaodong Mu; Christian Isaac; Trevor Schott; Johnny Huard; Kurt Weiss
Journal:  Sarcoma       Date:  2013-02-14

10.  Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.

Authors:  Sarah B Whittle; Katharine Offer; Ryan D Roberts; Amy LeBlanc; Cheryl London; Robbie G Majzner; Alex Y Huang; Peter Houghton; E Alejandro Sweet Cordero; Patrick J Grohar; Michael Isakoff; Michael W Bishop; Elizabeth Stewart; Emily K Slotkin; Emily Greengard; Scott C Borinstein; Fariba Navid; Richard Gorlick; Katherine A Janeway; Damon R Reed; Pooja Hingorani
Journal:  Pediatr Blood Cancer       Date:  2021-06-16       Impact factor: 3.838

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.